ClinicalTrials.gg

Program

Vinblastine

Also written as “vinblastine sulfate”.

Its studies are mostly in Hodgkin Disease · Carcinoma, Renal Cell, led by 3 companies.

Furthest: phase 4, since Feb 14, 20254 company-led studies, 2 open or runningNext primary completion: Mar 31, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda22 open or runningphase 4since Feb 14, 2025Nov 11, 2016Mar 31, 2028phase 4 · NCT06831370
Hoffmann-La Roche10 open or runningphase 2since Aug 23, 2007Aug 23, 2007none ahead
Hope Cancer Institute10 open or runningphase 2since Nov 1, 1999Nov 1, 1999none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 1, 1999First study: phase 2 study in Kidney NeoplasmsNew to Hope Cancer InstituteHope Cancer Institute · NCT00003181 · 35 enrolled · United States
  2. Aug 23, 2007Hoffmann-La Roche's first study: phase 2 study in Carcinoma, Renal CellNew to Hoffmann-La RocheHoffmann-La Roche · NCT00520403 · 25 enrolled · Germany
  3. Nov 11, 2016Takeda's first study: phase 2 study in Hodgkin DiseaseNew to TakedaTakeda · NCT02979522 · 59 enrolled · United States, Brazil, Italy and more
  4. Feb 14, 2025Phase 4 study in Hodgkin DiseaseTakeda · NCT06831370 · 124 planned · India

Ahead

  1. Mar 31, 2028Primary completion: phase 4 study in Hodgkin DiseaseTakeda · NCT06831370

TargetBeta

“Tubulin inhibitor”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
PaclitaxelruleHoffmann-La Rochephase 4202
DocetaxelruleSanofiphase 4199
cabazitaxelruleSanofiphase 421
desoxyepothilone Brulebeijing-biostar-pharmaceuticals-co-ltdphase 319
plinabulinrulebeyondspring-pharmaceuticals-incphase 38

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06831370Hodgkin Disease · India4RecruitingTakedaMar 31, 2028124
NCT02979522Hodgkin Disease · United States, Brazil, Italy and more2Active, not recruitingTakedaMay 5, 202059
NCT00520403Carcinoma, Renal Cell · Germany2CompletedHoffmann-La RocheMar 201025
NCT00003181Kidney Neoplasms · United States2UNKNOWNHope Cancer Institute35

How it is read

Names in the registry

  • “Vinblastine”, 3 entries
  • “vinblastine sulfate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.